LSP Life Sciences Fund generates net return of 39% in 2017
Amsterdam, January 16 2018 - LSP, the European life sciences investment group, today announced it has reached its 10 year milestone investing in listed life sciences securities with the LSP Life Sciences Fund generating +39% net return in 2017.
Commenting on the milestone, Mark Wegter, Managing Partner at LSP says: “Our activities as a public equity investor are rooted in our history as a private equity investor. That has enabled us to apply the knowledge and expertise, built up over a period of 25 years, to the public equity field. We started our public equity journey back in 2008. Since then, our specialist investment strategy and focus have proven to work and generate value for our investors.”
“From 2008 up to and including 2017, we have generated a total gross return in excess of +900% (+26% per annum). This return, known as the LSP Growth Composite, includes both our activities for individual mandates and our activities for the LSP Life Sciences Fund in the past 10 years. It represents the most accurate and longest-term measure of our performance as a public equity fund manager.”
In 2017, the LSP Life Sciences fund performed extremely well. Such in spite of the continued political and market turmoil which impacted the healthcare sector, although fortunately less extreme than in 2016, the worst year we have experienced to date in terms of performance. In 2017 the Fund delivered – on a net basis, after management and performance fees - a stellar return of +39%.
“This performance represents not the best, but one of the best returns we have achieved across our entire public investment franchise in the past 10 years. Only 2010 and 2014 were better with returns of +63% and +48% (gross) respectively. Our commitment to our long held strategy to focus on the companies with the potential to deliver true innovation and significant benefits to patients, was again proven to be the winning strategy in 2017,” Mark Wegter comments.
The LSP Life Sciences Fund is open-ended and publicly listed in the fund segment of the Euronext Amsterdam stock exchange. As such, it allows investors to buy and sell shares of the fund at any time, via their (internet) bank or broker. The fund’s Bloomberg ticker is LSP NA and its ISIN Code is NL0009756394.
This information (“Information”) does not constitute an offer for, or an invitation to subscribe to or purchase, any shares of the LSP Life Sciences Fund in any jurisdiction to any person to whom it is unlawful to make such offer or invitation in such jurisdiction. Persons into whose possession this Information comes are required to inform themselves about and observe any such restrictions. The manager of the LSP Life Sciences Fund, LSP Advisory B.V., is licensed and regulated by the Dutch Financial Markets Authority (Autoriteit Financiële Markten). More information of the LSP Life Sciences Fund can be found in the fund’s prospectus which is available via our website and the following link.
For inquiries or further assistance please contact:
Managing Partner LSP« back to overview